The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 12, 2017

Filed:

Apr. 27, 2015
Applicant:

University of Miami, Miami, FL (US);

Inventors:

Eckhard R. Podack, Coconut Grove, FL (US);

Vadim Deyev, Miami, FL (US);

Robert Levy, Cooper City, FL (US);

Assignee:

UNIVERSITY OF MIAMI, Miami, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61K 35/13 (2015.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 35/13 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/241 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5152 (2013.01); C07K 2317/14 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.


Find Patent Forward Citations

Loading…